The first session ofthis meeting, chaired by Professor L Collier, was designed to explain product liability, its implications for the NHS and the medical profession in general. Mr J D Evans <Regional Legal Adviser to Trent RHA) outlined the legal aspects of product liability in the NHS; Mr A W Hunter (Regulatory Controller, The Wellcome Foundation Ltd) spoke concerning product liability and the pharmaceutical industry, and Dr I M Sanderson (Under Secretary of the Medical Defence Union (MDU», detailed the MDU guidelines on product liability. Dr Marcela Contreras chaired the second session, which focused on product liability with specific reference to blood transfusion and chemical pathology. Dr W Wagstaff (Director NBTS Sheffield) and Dr A C Ames (Consultant Chemical Pathologist, Neath General Hospital) were the invited speakers.
The report that follows is a collation of the papers that were presented.
The Consumer Protection Act (CPA) implements the European Directive on Product Liability under which all members of the European Community are obliged to introduce strict liability laws for defective products. Product liability became a reality in the United Kingdom on 1 March 1988 when Part I of the CPA came into force. No liability is imposed under the Act in respect of goods supplied before March 1988. The CPA is in addition to, not instead of, the law of Tort and the Sale of Goods Act, and gives people additional rights by safeguarding the consumer from goods which do not reach a reasonable level of safety.
Definitions and terminology
The essence of product liability is that if a defect in a product causes damage the producer is liable unless there is a defence.
Defect: a product is defective if its safety is not such as persons are generally entitled to expect. In deciding whether a product is defective a court will take into account all the relevant circumstances, for example, any instructions or warnings that are given with the product and what might reasonably be expected to be done with it.
Product: products are essentially goods: they can be manufactured, won or abstracted.
Causes:
The plaintiff will have to show that, on the balance of probabilities, the defect caused the damage. This will place a heavy but necessary, burden of proof on the plaintiff.
Damage: the Act covers death, personal injury or damage to private property valued above £275.
Producer:A 'producer' is the person who manufactured the product, but also includes importers, 'ownbranders' or suppliers. If the product is produced outside the UK, then the liability for the goods rests with the first importer of the goods into the European Community. However, the UK importer becomes liable if the original importer cannot be identified, Parties who put their own name on the goods or give the impression that they are the producers thus take on the liability for the goods. If the supplier of a product cannot identify the producer then the supplier is liable when any damage is caused by the product.
Liability: the Act enforces strict liability so that if the product is defective, damage was suffered and the damage was caused by the defect, then the producer (importer, ownbrander, supplier) is liable. It is not necessary for the plaintiff to prove negligence.
Defence: a producer can avoid liability if he can provide a defence. Those that relate to the medical profession are: ethe producer did not supply the product, eg it was stolen or copied. ethe defect was caused by complying with the law. This however will not necessarily discharge the producer from liability, as the producer would have to show that the defect was the inevitable result ofcompliance. ethe defect was not in the product at the time it was supplied, eg a product became defective due to poor handling or storage by the supplier. Similarly this would include any alterations by a supplier to the original specifications of the product. ea producer can invoke the 'state of the art' defence by showing that the state of scientific and technical knowledge at the time he supplied the product was not such as to enable the existence of the defect to be discovered. Several countries in the EEC including France, Belgium, Luxemburg and Denmark do not allow this defence. At present it is understood that the European Commission may commence infringement proceedings against the UK, as legal opinion has suggested that the UK has gone further in protecting the manufacturer than allowed in the Directive. However, it is argued that it is important to retain this defence so that research and development of products and techniques is not impeded. As a producer: NHS manufacture covers a wide range of products including some pharmaceuticals, diagnostic reagents and kits, disablement aids and appliances, dressing packs and blood components, to name just a few. In addition, if a piece of equipment or a product is modified, then the person or department 80 doing may becomea producer: for example, bending a venepuncture needle prior to use or modifying an orthopaedic insert to suit an individual patient; or by washing or filtering a blood component prior to infusion. Modifications may be defensible only if the changes are in accord with the original manufacturer's instructions and guidelines. What constitutes 'manufacture' will need to be determined in individual cases and is to some extent dependent on the scale of activity. For example a pharmacy providing total parenteral nutrition would be deemed to be a manufacturer but a nurse adding potassium chloride to an intravenous infusion would not. The nurse could not be sued under the CPA but if her actions were negligent she could be sued under the law of Tort.
In any manufacturing practice it is important that every effort is made to avoid producing defective products. Therefore products should conform to any relevant standards or specifications which exist and records kept to demonstrate conformity. Products should be manufactured with traceability of eonstituents and components and, where appropriate, compliance with Good Manufacturing Practice should be demonstrated. This is not a defence under the Act but will reduce the likelihood of claims and increase the confidence level of any in-house manufacturing activities.
As a supplier: where a patient is supplied a product which is later shown to have been defective and to have caused injury or damage, the supplying Health Authority may incur liability for that defective product unless either the producer or the authority's supplier can be identified. This will require accurate and detailed record keeping to show clearly from whom, and when a product was obtained and to whom, and when it was supplied. For example, it should be possible to trace a blood component from the point of production, to exactly when and to whom it was infused, including all intermediary steps such as its storage and crossmatching. Similarly, records for all drugs dispensed showing the supplier (particularly in relation to generic prescribing), serial or batch number and date of issue must be available.
It is important to demonstrate that any instructions in relation to the use, storage or expiry dates of products are strictly observed and are also, ifrelevant, passed onto the user. If a manufacturer can show that a product was not used or issued in accordance with his instructions then he can disclaim his liability.
As a keeper: if a patient suffers damage from the use of a piece of equipment the liability rests with the producer of that equipment, provided that the equipment has been maintained and used in accordance with the manufacturer's instructions. Programmed planned maintenance of all equipment is therefore essential. Such maintenance is also a general requirement under the Health and Safety at Work Act, 1974.
The legislation involving equipment applies only to those items less than 10 years old and purchased after March 1988. A patient harmed by equipment more than 10 years old would have no claim under this legislation against the manufacturer. However the patient could choose to pursue a claim against a Health Authority on the grounds of negligence. In this situation the NHS would be condoning the continued use of an instrument which was out of 'legal warranty'. Inventories of all instruments should be kept up to date so that the health authorities can be given due warning when equipment is approaching 10 years of age.
Another point of advice relates to equipment which is not owned, but is on loan from a manufacturer or supplier, eg for trial or evaluation. It is important that the position of responsibility for liability is understood by both parties and stated in the contractual agreement.
General comment
The CPA has potentially serious implications for the medical profession. The risks cannot be ignored, but can be safeguarded against and appropriately 'managed'. Strict record keeping relating to the procurement, use, modification and supply of products will be crucial if liability is to fall only upon the manufacturer of faulty products or components. The CPA will only apply to products supplied after 1 March 1988 and the plaintiff must bring his court action within three years of being injured by the plaintiff's product. No claims can be made regarding the product more than 10 years after it has been placed on the market. As the obligation arising from liability lapses only after a period of 10 years and up to one year is allowed for the serving of a writ, such records should be retained for a period of at least 11 years. In situations where there is a long shelf life of products, for example some blood products, it has been recommended that records be kept for 15 years. It is recognizedthat the introduction and maintenance of new or more sophisticated systems of record keeping will add substantially to time and costs. Similarly, the future costs of any successful claims will be a Health Authority liability. Therefore, the Health Authority will need to make its own decision in balancing the costs of additional record keeping against the likelihood of claims.
Where appropriate the patient should be informed about the risks of using a product and instructed on how the product should be correctly used, to reduce the likelihood of a claim. Although a patient cannot waive his/her rights under the CPA, it is still advisable to have written confirmation that the appropriate warnings or information regarding a product were given prior to its use.
To minimize the possible liability of Health Authorities under the Act means that all doctors and departments must take a fresh look at their working practices. Changes are inevitable. For example, an in-house assay may have to be abandoned even if the commercial alternative is more expensive, and possibly less suitable. However, it is most important that this Act does not prevent development and does not result in defensive attitudes to the detriment of our patients.
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